Skip to content
  • Home
  • Services
  • Providers
  • Patients
    • Patient Education
    • Patient Resources
    • FAQ
  • About
    • About Us
    • News
    • Careers
  • Locations
    • Peach Street Office
    • John F. Kennedy Center
    • Parade Street Office
  • Contact Us
  • DONATE

Call Us Today! (814) 453-6229

Find Our Locations
Patient Portal
MHEDSMHEDS
MHEDSMHEDS
  • Home
  • Services
  • Providers
  • Patients
    • Patient Education
    • Patient Resources
    • FAQ
  • About
    • About Us
    • News
    • Careers
  • Locations
    • Peach Street Office
    • John F. Kennedy Center
    • Parade Street Office
  • Contact Us
  • DONATE

Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals

August 12, 2021

Other fully vaccinated individuals do not need an additional vaccine dose right now

For Immediate Release: August 12, 2021

Source: US Food and Drug Administration

Español

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is scheduled to meet Friday to discuss further clinical recommendations regarding immunocompromised individuals. Today’s action does not apply to people who are not immunocompromised.

“The country has entered yet another wave of the COVID-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease. After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna Vaccines,” said Acting FDA Commissioner Janet Woodcock, M.D. “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19. As we’ve previously stated, other individuals who are fully vaccinated are adequately protected and do not need an additional dose of COVID-19 vaccine at this time. The FDA is actively engaged in a science-based, rigorous process with our federal partners to consider whether an additional dose may be needed in the future.”

People who are immunocompromised in a manner similar to those who have undergone solid organ transplantation have a reduced ability to fight infections and other diseases, and they are especially vulnerable to infections, including COVID-19. The FDA evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna Vaccines in these individuals and determined that the administration of third vaccine doses may increase protection in this population. These patients should be counseled to maintain physical precautions to help prevent COVID-19. In addition, close contacts of immunocompromised persons should get vaccinated, as appropriate for their health status, to provide increased protection to their loved ones.

It is recommended that immunocompromised individuals discuss monoclonal antibody treatment options with their health care provider should they contract or be exposed to COVID-19. The FDA has authorized monoclonal antibody treatments for emergency use during this public health emergency for adults and pediatric patients (ages 12 and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. One authorized product includes use for preventative (prophylaxis) treatment after being exposed to SARS-CoV-2; however, this product is not a substitute for vaccination. 

The Pfizer-BioNTech COVID-19 Vaccine is currently authorized for emergency use in individuals ages 12 and older, and the Moderna COVID-19 Vaccine is authorized for emergency use in individuals ages 18 and older. Both vaccines are administered as a series of two shots: the Pfizer-BioNTech COVID-19 Vaccine is administered three weeks apart, and the Moderna COVID-19 Vaccine is administered one month apart. The authorizations for these vaccines have been amended to allow for an additional, or third, dose to be administered at least 28 days following the two-dose regimen of the same vaccine to individuals 18 years of age or older (ages 12 or older for Pfizer-BioNTech) who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

The EUA amendments for the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine were issued to Pfizer Inc. and ModernaTX Inc., respectively.

Related Information

  • Pfizer-BioNTech COVID-19 Vaccine
  • Moderna COVID-19 Vaccine

###

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


Inquiries

Media: FDA Office of Media Affairs 301-796-4540Consumer: 888-INFO-FDA

You also might be interested in

A woman sits by a window, looking outside thoughtfully. The text on the left reads, Lets talk about seasonal depression. Snowy scenery is visible through the window.

Understanding Seasonal Depression: Shedding Light on the Winter Blues

Jan 16, 2024

As winter approaches, many people experience seasonal depression, also known[...]

A child stands on a scale displaying the word HELP. Text beside reads: MHEDS: Multi-Cultural Health Evaluation Delivery System. September is NATIONAL CHILDHOOD OBESITY Awareness Month.

Childhood Obesity Awareness Month: Promoting Healthy Habits

Sep 1, 2023

September marks Childhood Obesity Awareness Month, a crucial time to[...]

Cover of the MHEDS Annual Report 2021, Pandemic Edition, featuring a waterfront tower at sunset with lights reflected on the water.

MHEDS Annual Report 2021

Mar 24, 2022

Letter to the Community The rich history of MHEDS began[...]

Categories

  • Capital Campaign
  • COVID-19
  • Erie Thrives
  • Feature Story
  • Health Insurance
  • Health Services
  • JFK Center
  • Locations
  • News
  • Parade Street
  • Patient Education
  • Peach Street
  • Providers
  • Uncategorized

Latest Posts

Flu Season Is Here: What to Know

October 5, 2026

Dr. Mary Lasher shares what patients should know about flu shots, prevention, treatment, common misconceptions, and staying healthy this flu season.

Healthy Aging & Fall Prevention

September 7, 2026

Small changes can help you age safely and confidently. Learn practical tips for staying active, preventing falls, and protecting your independence.

MHEDS Secures Federal Health Center Funding to Expand Access to Care

August 14, 2026

MHEDS Selected for Federal New Access Point Award, Advancing...

We Want to Care For You! Call (814) 453-6229, (814) 616-7730, or (814) 377-0377. Click Here to Email Us
Company Logo

Our Locations

  • Peach Street Location
  • 2928 Peach Street, Erie, PA 16508
  • (814) 453-6229
  • JFK Center Location
  • 2021 E 20th St, Erie, PA 16510
  • (814) 616-7730
  • Parade Street Location
  • 826 Parade Street, Erie PA 16503
  • (814) 377-0377
FQHC Logo

© 2026 — Multi-Cultural Health Evaluation Delivery System, Inc. All rights reserved. Website designed by Strategic Arc Limited. MHEDS is a site for COVID-19 testing. This project is in part supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $146,777 with 20 percentage funded by HRSA/HHS and $603,223 and 80 percentage funded by nongovernment source(s). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA/HHS, or the U.S. Government.

  • Home